The Boston Business Journal (Free subscription) | 11/20/2008
Synta Pharmaceuticals Corp. treated the first patient in the clinical trial of its proprietary prostate-cancer drug elesclomol.
The East Bay Business Times (Free subscription) | 10/16/2008
Cell Genesys Inc. shares dropped sharply today as the South San Francisco company said it will cut more than 200 jobs, is exploring its sale or liquidation, and stopping the late-stage trial of its prostate cancer drug. (CEGE)
Seattle Times (Free subscription) | 10/07/2008
Dendreon said Monday that Provenge, its prostate-cancer drug, improved patient survival rates — but not quite enough for the interim results it unveiled to justify an accelerated bid for Food and Drug Administration approval.
Forbes (Free subscription) | 11/07/2008
The drug developer reports a wider loss waiting on its prostate cancer drug.
The Puget Sound Business Journal (Free subscription) | 10/06/2008
Dendreon Corp. said that its Provenge prostate cancer drug reduced deaths by 20 percent in a recent trial. (DNDN)
Seattle Times (Free subscription) | 10/06/2008
Dendreon's interim results from a trial of its prostate-cancer drug Provenge show mixed results, but stock soars anyhow.
